Last reviewed · How we verify
Placebo for olaparib
A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.
A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect. Used for Control arm in Phase 3 clinical trial for olaparib.
At a glance
| Generic name | Placebo for olaparib |
|---|---|
| Also known as | Placebo |
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Placebos are inert substances used as controls in clinical trials to establish the efficacy of the active drug being tested. In this case, it serves as the control arm in a Phase 3 trial comparing olaparib (a PARP inhibitor) to placebo. Any observed effects in the placebo group are attributable to the placebo effect or natural disease progression.
Approved indications
- Control arm in Phase 3 clinical trial for olaparib
Common side effects
Key clinical trials
- APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation (PHASE2)
- Protecting the Kidney's Proximal Tubules From Platinum-Based Chemotherapy Toxicity (PHASE2)
- D9319C00001- 1L OC Mono Global RCT (PHASE3)
- A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008) (PHASE3)
- Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION) (PHASE2)
- A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU) (PHASE2)
- Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer (PHASE3)
- Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo for olaparib CI brief — competitive landscape report
- Placebo for olaparib updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI